Modulation of Inflammatory Indices by Omega-3 Fatty Acids Supplementation in Hemodialysis: A Clinical Trial Approach
Shafaei Kachaei H, Abbasi Mobarakrh K, Azaryan F, Torkaman M, Askarpour SA, Harsini AR, Fahimzad FS, Mousavi Mele M, Hoseinzadeh Liavoli M, Masoomi Golujeh N, Ataie Kashki S, Khoshdooz S, Doaei S, Khosravi M, Gholamalizadeh M
Clinical and translational science · 0 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Shahid Beheshti University
- Universidad u hospital
- Gilan University of Medical Sciences
- Subvenciones
- Shahid Beheshti University (IRCT20151226025699N6)
Según 2 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2026-04-27 · Clin Transl Sci · vol. 19 · número 5 · pág. e70531
- Editorial
- Wiley
- Citado
- 0 citas · más que el 24% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 9 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC
- Áreas de investigación
- Fatty Acid Research and Health · Dialysis and Renal Disease Management · Antioxidant Activity and Oxidative Stress
- Palabras clave
- omega-3 fatty acids, dietary supplementation, chronic kidney disease, hemodialysis, systemic inflammation, C-reactive protein, interleukin-6, inflammatory markers, anti-inflammatory activity, omega-6 fatty acids, n-6/n-3 ratio
- MeSH
- humans, inflammation, fatty acids, omega-3, c-reactive protein, interleukin-6, renal dialysis, dietary supplements, adult, aged, middle aged, female, male, renal insufficiency, chronic, biomarkers
15 autores
- Hanieh Shafaei🇮🇷Guilan University of Medical Sciences
- Khadijeh Abbasi Mobarakeh🇮🇷Isfahan University of Medical Sciences
- Fatemeh Azaryan🇮🇷Zahedan University of Medical Sciences
- Mahdie Torkaman🇮🇷Shahid Beheshti University of Medical Sciences
- Seyed Ali Askarpour🇮🇷Tehran University of Medical Sciences
- Asma Rajabi Harsini🇮🇷Tehran University of Medical Sciences
- Fatemeh Sadat Fahimzad🇮🇷Tehran University of Medical Sciences
- Mahdi Mousavi Mele🇮🇷Tabriz University of Medical Sciences
- Marziyeh Hoseinzadeh Liavoli🇮🇷Guilan University of Medical Sciences
- Neda Masoomi Golujeh🇮🇷Guilan University of Medical Sciences
- Sanaz Ataie Kashki🇮🇷Guilan University of Medical Sciences
- Sara Khoshdooz🇮🇷Guilan University of Medical Sciences; Razi Hospital
- Saeid Doaei🇮🇷Shahid Beheshti University; Shahid Beheshti University of Medical Sciences
- Masoud Khosravi🇮🇷Guilan University of Medical Sciences; Razi Hospital
- Maryam Gholamalizadeh🇮🇷Shahid Beheshti University; Shahid Beheshti University of Medical Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Chronic kidney disease (CKD) is closely associated with systemic inflammation. This randomized controlled trial aimed to evaluate the effects of omega-3 fatty acids supplementation on inflammatory markers in patients with CKD undergoing hemodialysis. Eligible participants with CKD receiving hemodialysis were randomly assigned to either an intervention group or a control group. The intervention group received three capsules of omega-3 fatty acids (3 g/day) for two months, while the control group received placebo capsules containing medium-chain triglyceride (MCT) oil. Inflammatory markers, including C-reactive protein (CRP) and interleukin-6 (IL-6), were measured both before and after the interventions. The results showed that CRP levels increased from 9.86 ± 12.64 to 11.46 ± 22.23 mg/L in the intervention group and from 5.24 ± 9.01 to 5.61 ± 7.93 mg/L in the control group (p = 0.11). Similarly, IL-6 levels increased from 17.84 ± 14.08 to 81.82 ± 66.22 pg/mL in the intervention group and from 14.96 ± 18.41 to 56.73 ± 115.45 pg/mL in the control group (p = 0.53). No statistically significant group differences were observed after adjusting for confounders such as age, sex, body mass index (BMI), smoking, dietary intake, and pre-existing diseases. The study findings showed that a two-month intake of omega-3 fatty acids supplements did not have a significant impact on reducing the levels of inflammatory markers in CKD patients undergoing hemodialysis. Larger trials with longer durations are warranted. Study Highlights What is the Current Knowledge on the Topic? ○ Omega-3 fatty acids have anti-inflammatory properties and are reported to be potentially beneficial in reducing inflammation associated with CKD, but the evidence regarding the effectiveness of omega-3 supplements in reducing inflammatory markers in this population remains inconsistent. What Question did this Study Address? ○ What is the effect of omega-3 fatty acids supplementation for 2 months on CRP and IL-6 levels in patients with CKD undergoing hemodialysis? What Does This Study Add to Our Knowledge? ○ Contrary to previous studies, this study found that omega-3 fatty acids supplementation did not significantly reduce CRP or IL-6 levels compared with placebo over 2 months and that short-term supplementation is not sufficient to reduce systemic inflammation in hemodialysis patients. How Might this Change Clinical Pharmacology or Translational Science? ○ These findings suggest that short-term omega-3 fatty acids supplementation may not be sufficient in reducing inflammatory markers in CKD patients undergoing hemodialysis and highlight the need for larger-scale clinical trials with different doses and longer durations to investigate nutritional or pharmacological strategies.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.